initial public offering price up to 175,000 shares of our common stock, or approximately five percent (5%) of the shares
125,730 options to acquire shares of our common stock pursuant to our 2016 Equity Incentive Plan at exercise prices ranging from
Pure-Vu system is currently our sole product and we are completely dependent on the successful marketing and sale of this
for sale at the initial public offering price up to 175,000 shares of our common stock, or approximately five percent
of our common stock available for sale to the general public in this offering will be reduced by the number of shares sold
of the period or the original date of issuance, if later.As of September 30, 2017ActualPro Forma (1)Pro Forma as Adjusted (2)(3)(unaudited)(in thousands)Balance Sheet Data:Cash and cash equivalents$9,827$9,827$28,247Working capital9,6289,62828,048Total assets11,76311,76330,183Contingent royalty obligation1,6161,6161,616Series A convertible preferred stock(*)--Accumulated deficit(35,348)(35,348)(35,348)Total stockholdersâ€™ equity$8,970$8,970$27,390(*)
including our financial statements and the related notes thereto, before deciding whether to invest in shares of our common stock.
The 2017 Tax Act, among other things, includes changes to U.S. federal tax rates, imposes significant additional limitations on the deductibility of interest and net operating losses, allows
or a new indication for use of, or other significant change in, an existing medical device obtain either FDA 510(k) pre-market
may be unable to obtain or maintain governmental approvals to market our Pure-Vu system outside the United States, including the
may be unable to obtain or maintain governmental approvals to market our Pure-Vu system outside the United States, including the
and will control our company for the foreseeable future, including the outcome of matters requiring stockholder approval.When this offering is completed our officers,
compensation plan resulting from the annual increase in the number of shares of our common stock available for issuance under
in this offering, and options to purchase an aggregate of up to 1,883,845 shares of our common stock, at exercise prices ranging
terms of the Israeli government participation also require that products developed with IIA grants be manufactured in Israel and
current and future capital requirements to support our development and commercialization efforts for the Pure-Vu system and
between the initial public offering price per share of our common stock and the pro forma as adjusted net tangible book value
pro forma net tangible book value, plus the effect of the sale of shares of our common stock in this offering at the assumed initial
additional shares of our common stock reserved for future issuance under our 2016 Equity Incentive Plan as of September 30,
additional shares of our common stock reserved for future issuance under our 2016 Equity Incentive Plan as of September 30,
additional shares of our common stock reserved for future issuance under our 2016 Equity Incentive Plan as of September 30,
additional shares of our common stock reserved for future issuance under our 2016 Equity Incentive Plan resulting from the
additional shares of our common stock reserved for future issuance under our 2016 Equity Incentive Plan resulting from the
additional shares of our common stock reserved for future issuance under our 2016 Equity Incentive Plan resulting from the
to us by our existing stockholders and by new investors purchasing shares of common stock in this offering at the assumed initial
in purchasing up to an aggregate of approximately $7.5 million in shares of our common stock in this offering at the initial
in purchasing up to an aggregate of approximately $7.5 million in shares of our common stock in this offering at the initial
in purchasing up to an aggregate of approximately $7.5 million in shares of our common stock in this offering at the initial